Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAARD: Biotype-assigned Augmentation Approach in Resistant Late-Life Depression
NCT07810738Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 2
01
Overview
Phase 2, randomised trial of aripiprazole and bupropion in treatment-resistant depression (TRD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Remission from Depression at 10 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
aripiprazolebupropion
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07810738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07810738.